markcl208041

Ph.D. in Information Science and Technology. Immuno-oncology, Precision medicine, Translational science, Single cell,Biomarker,Bioinformatics.Tweets my own.

[Roberto Borea, MD @RobertoBoreaMD]

#ASCO26 is coming! 🩸

Check the selected #liquidbiopsy oral presentations for this year by the @isliquidbiopsy Young Committee!

Save the dates 📅 and look forward to our upcoming editorial! 📰

@OSUCCC_James @ChristianRolfo @UmbertoMalapel1 @drgandara

[Paolo Tarantino @PTarantinoMD]

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

[Yakup Ergün @dr_yakupergun]

ESMO HANDBOOK OF CANCER GENETICS AND GENOMICS #ESMO25

List of Actionable Genes and the FDA-approved Molecularly Matched Drugs👇

[Dr Amol Akhade @SuyogCancer]

Summary of all trials post tki progression in NSCLC.
SACHi
Herthena- lung 02
OptiTrop -lung03
Harmoni global ( presss release)
Mariposa 2
Note that Partitumab is withdrawn by company 2 days ago.

Cross trial comparisons for all 5 trials @dr_yakupergun @Alfdoc2 @RenoHemonc @StephenVLiu @ASCO #asco25 @OncoAlert

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[NEJM @NEJM]

Presented at #ASCO25:

In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial: https://t.co/APbBkRhcPO

@ASCO

[Kohei shitara @KoheiShitara]

A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with @NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. @ASCO @OncoAlert @DaiichiSankyo @DaiichiSankyoUS @AstraZeneca @Oncology_at_AZ

[Jun Gong, MD @jgong15]

So many same day high-impact publications from #ASCO25 #GI onc oral presentations:

https://t.co/jKQghOSpVS

https://t.co/rKtLOdvjRG

https://t.co/cZIp4mGTCU

https://t.co/QiE0CwXxo5

https://t.co/mzR0xV38OF

@OncoAlert @Cecchini_OncMD @GIMedOnc @IbrahimSahinMD1 @Innov_Medicine

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Today at #ASCO25, I’ll be presenting findings from the VERITAC-2 study on vepdegestrant in ER+/HER2- metastatic #breastcancer, the most common subtype, demonstrating a 43% risk reduction in progression/death for ESR1-mutant patients. @NEJM https://t.co/GHvyyWVebZ

[Oncology Brothers @OncBrothers]

Day 2 #ASCO25 highlights:

1. #VERITAC2: Vepdegestrant HR+ mBC

2. #INAVO120 (update): Inavolisib HR+ mBC

3. #ASCENT04: Sacituzumab mTNBC

4. #CM577 (update): Adj Nivo GEJ/Gastric

5. #DESTINYGastric04: TDXd HER2+ GEJ/Gastric

6. #KN564 (update): Adj Pembro ccRCC

@ASCO

1/8

[Oncology Brothers @OncBrothers]

Day 1 #ASCO25 highlights:

1. Review on recent approvals

2. #BREAKWATER (update): BRAF+ mCRC

3. #CM8HW (update): MSI-H mCRC

4. #DYNAMIC: ctDNA in colon ca

5. #CAIRO6: periOP Rx in peritoneal mets

#OncTwitter @ASCO

1/6

[Matteo Lambertini, MD PhD @matteolambe]

What a fantastic discussion by super @DrHBurstein from @DanaFarber of the #EMBER3 trial data at the general session 1 #SABCS24

@OncoAlert @SABCSSanAntonio @UTHealthSA @DFCI_BreastOnc @dfcidatascience @DanaFarberNews

[Cancer Cell @Cancer_Cell]

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade https://t.co/GW7x8YYh7H

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Current and emerging strategies for the prevention of hepatocellular carcinoma https://t.co/GUfHuYh3ch

[Cancer Cell @Cancer_Cell]

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy https://t.co/FvfWBZ1CP7

[FDA Oncology @FDAOncology]

FDA issued final guidance, Use of Circulating Tumor DNA for Curative Intent Solid Tumor Drug Development, to help sponsors using ctDNA as a biomarker in trials under an IND or to support approval of products for treating early-stage solid tumors.
https://t.co/xm4IPGFKRH

[Giannis Mountzios @g_mountzios]

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in@NatRevClinOncol highlighting:

➡️Strategies to improve on 1L 3rd Gen TKI mono therapy
➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape

@LeXiuning @danieltanmd @RamalingamMD @IASLC
#LCSM #some

[Waggoner Lab @LabWaggoner]

REVIEW @NatRevImmunol @PamSharmaMDPhD
Next-generation combination approaches for immune checkpoint therapy
https://t.co/Nku9C5jH3U

[Cancer Discovery @CD_AACR]

In the November Issue: The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. https://t.co/qLAy1bDath

By @raffcolo, @PTarantinoMD, and colleagues @ZymeworksInc @DanaFarber

[Yakup Ergün @dr_yakupergun]

Epigenetics-targeted drugs: current paradigms and future challenges

Many drugs are being developed in every field of oncology👇

https://t.co/ykWjARprot